Terri Shoemaker founded Medac Pharma in June 2012 and served as President and Chief Executive Officer and a member of our the board of directors. Medac Pharma was acquired by Medexus Pharmaceuticals in October 2018. Since developing the business plan that led to a shareholder decision to launch the organization, Ms Shoemaker has implemented an ambitious commercial strategy in support of their commercial product for the treatment of rheumatoid arthritis.

Prior to joining Medexus Pharma, Ms. Shoemaker served as Vice President of Sales at InterMune where she developed a large-scale commercial sales infrastructure in preparation for the launch of a treatment for idiopathic pulmonary fibrosis. Before joining InterMune in 2009, Ms. Shoemaker co-founded BioPharm Strategic Solutions, providing commercial, operational and strategic guidance for start-up pharmaceutical and biotechnology organizations. In 2002 Ms. Shoemaker joined Pharmion Corporation, serving as National Sales Director and then Sr. Director US Commercial Operations building and leading a specialty oncology organization. In 2008 when Celgene Corporation acquired Pharmion, Ms. Shoemaker remained as Executive Director of Strategic Commercial Operations working as part of the executive transition team charged with building the new and fully aligned commercial organization. Ms. Shoemaker began her career at DuPont Pharmaceuticals, which was acquired by Bristol Myers Squibb in 2000, where she held a number of leadership positions including Senior Director of Sales, Director of Clinical Development & Education, and Director Marketing and Health Management.

Ms. Shoemaker holds B.S. degrees in Communication Science and Psychology from Missouri State University, and a M.S. degree in Communication Science and Disorders from University of Central Missouri.

Developing new molecules and adding value to established agents

Approved Products